Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS; MOPH TAVEG Collaboration..

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57. doi: 10.1089/aid.2012.0103.

2.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators..

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756.

3.

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC.

PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665.

4.

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.

Peachman KK, Karasavvas N, Chenine AL, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael NL, Kim JH, Alving CR, Rao M.

PLoS One. 2015 Dec 1;10(12):e0143895. doi: 10.1371/journal.pone.0143895.

5.

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, Nitayaphan S, de Souza M, Korber B, Koup R, Bailer RT, Mascola JR, Pinter A, Montefiori D, Haynes BF, Robb ML, Rerks-Ngarm S, Michael NL, Gilbert PB, Kim JH.

PLoS One. 2013;8(1):e53629. doi: 10.1371/journal.pone.0053629.

6.

Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.

Spurrier B, Sampson J, Gorny MK, Zolla-Pazner S, Kong XP.

J Virol. 2014 Apr;88(8):4100-12. doi: 10.1128/JVI.03153-13.

7.

The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.

O'Connell RJ, Kim JH, Excler JL.

Expert Rev Vaccines. 2014 Dec;13(12):1489-500. doi: 10.1586/14760584.2014.951335. Review.

PMID:
25163695
8.

Cryptic determinant of α4β7 binding in the V2 loop of HIV-1 gp120.

Tassaneetrithep B, Tivon D, Swetnam J, Karasavvas N, Michael NL, Kim JH, Marovich M, Cardozo T.

PLoS One. 2014 Sep 29;9(9):e108446. doi: 10.1371/journal.pone.0108446.

9.

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G.

J Virol. 2014 Jul;88(14):7715-26. doi: 10.1128/JVI.00156-14.

10.

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.

Steers NJ, Ratto-Kim S, de Souza MS, Currier JR, Kim JH, Michael NL, Alving CR, Rao M.

PLoS One. 2012;7(8):e42579. doi: 10.1371/journal.pone.0042579.

11.

The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.

Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.

Virology. 1998 Nov 10;251(1):59-70.

12.

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, Yates NL, Shen X, Tomaras GD, Ferrari G, Foulds KE, McDermott A, Kao SF, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Wagner R, Ding S, Pantaleo G, Esteban M.

J Virol. 2015 Aug;89(16):8525-39. doi: 10.1128/JVI.01265-15.

13.

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee.

Nicely NI, Wiehe K, Kepler TB, Jaeger FH, Dennison SM, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Robb ML, O'Connell RJ, Michael NL, Kim JH, Liao HX, Munir Alam S, Hwang KK, Bonsignori M, Haynes BF.

EBioMedicine. 2015 Jun 20;2(7):713-22. doi: 10.1016/j.ebiom.2015.06.016.

14.

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.

Karasavvas N, Karnasuta C, Savadsuk H, Madnote S, Inthawong D, Chantakulkij S, Rittiroongrad S, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Siriyanon V, Andrews CA, Barnett SW, Tartaglia J, Sinangil F, Francis DP, Robb ML, Michael NL, Ngauy V, de Souza MS, Paris RM, Excler JL, Kim JH, O'Connell RJ; MOPH-TAVEG Collaboration..

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86. doi: 10.1089/AID.2015.0034.

15.

Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.

Gohain N, Tolbert WD, Acharya P, Yu L, Liu T, Zhao P, Orlandi C, Visciano ML, Kamin-Lewis R, Sajadi MM, Martin L, Robinson JE, Kwong PD, DeVico AL, Ray K, Lewis GK, Pazgier M.

J Virol. 2015 Sep;89(17):8840-54. doi: 10.1128/JVI.01232-15.

16.

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.

Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD.

PLoS One. 2014 Feb 4;9(2):e87572. doi: 10.1371/journal.pone.0087572.

17.

Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.

Doran RC, Morales JF, To B, Morin TJ, Theolis R Jr, O'Rourke SM, Yu B, Mesa KA, Berman PW.

Mol Immunol. 2014 Nov;62(1):219-26. doi: 10.1016/j.molimm.2014.06.025.

18.

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.

Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Kijak GH, Bose M; RV144 Sequencing Team., Arroyo MA, O'Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB.

PLoS Comput Biol. 2015 Feb 3;11(2):e1003973. doi: 10.1371/journal.pcbi.1003973. Erratum in: PLoS Comput Biol. 2016 Jan;12(1):e1004733.

19.

HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

Rao M, Peachman KK, Kim J, Gao G, Alving CR, Michael NL, Rao VB.

Curr HIV Res. 2013 Jul;11(5):427-38.

20.

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; Thai AIDS Vaccine Evaluation Group..

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.

PMID:
17909315
Items per page

Supplemental Content

Support Center